VectivBio reunites ex-Therachon management, VCs for short bowel program

Eight months after a venture syndicate gained an exit via the sale of dwarfism company Therachon to Pfizer, the same investors have reunited to supply a $35 million round for VectivBio, a new spinout created to house a short bowel syndrome program left behind in the acquisition.

VectivBio AG will reunite several members of Therachon’s management team, as well as a syndicate that includes Versant Ventures, OrbiMed, Novo Holdings, Bpifrance, Tekla Healthcare Investors, Inserm Transfer Initiative and Cowen Healthcare Investments. Pfizer Inc. (NYSE:PFE) will hold a stake as well thanks to its prior stake in Therachon, VectivBio CEO Luca Santarelli told BioCentury...